Optimized method for screening atrial fibrillation in older adults
STROKESTOP III - Optimized Method for Atrial Fibrillation Screening
This study is testing a new way to find atrial fibrillation in older adults by comparing regular heart checks to checking only when they visit the doctor.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2200 (estimated) |
| Ages | 75 Years to 76 Years |
| Sex | All |
| Sponsor | Danderyd Hospital Academic / other |
| Locations | 2 sites (Stockholm and 1 other locations) |
| Trial ID | NCT06275503 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the detection of atrial fibrillation (AF) in individuals aged 75-76 by comparing systematic screening methods to opportunistic screening. Participants will receive a hand-held ECG device to monitor their heart rhythm regularly, with data sent for interpretation. The study will involve primary care facilities in the Värmland region, where patients will be randomized to either receive an invitation for systematic screening or be screened opportunistically during health visits. The goal is to identify new cases of AF, which can significantly increase stroke risk if untreated.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 75-76 residing in the Värmland region and listed at a primary care facility.
Not a fit: Patients currently undergoing oral anticoagulation treatment or those with known and treated atrial fibrillation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and treatment of atrial fibrillation, reducing the risk of stroke in older adults.
How similar studies have performed: Previous studies have shown that systematic screening can significantly increase the detection rates of atrial fibrillation compared to opportunistic methods.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged 75/76 in 2024 (born 1948, 1949) * Must reside in the region of Värmland * Must be listed at a primary care facility Exclusion Criteria: * Treatment with oral anti coagulation treatment (OAC) * Contraindications for OAC treatment * Prior atrial fibrillation * Unable to provide consent
Where this trial is running
Stockholm and 1 other locations
- Karolinska Institutet, Dept Med H — Stockholm, Sweden (Not_yet_recruiting)
- Region Värmland — Värmland, Sweden (Recruiting)
Study contacts
- Principal investigator: Emma Svennberg, MD PhD — Karolinska Institutet
- Study coordinator: Emma Svennberg, MD PhD
- Email: emma.svennberg@regionstockholm.se
- Phone: +46739584822
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.